Катетерное лечение пациентов с фибрилляцией предсердий и воспалением миокарда

Представлены современные данные о фибрилляции предсердий, подходах к терапии и возможности интервенционного способа лечения больных. Приведены данные о воспалительном поражении сердца и его взаимосвязи с аритмией.

1. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ et al. Worldwide Epidemiology of Atrial Fibrillation: A Glo­bal Burden of Disease 2010 Study. Circulation. 2014;129(8):837–47. DOI: 10.1161/CIRCULATIONAHA.113.005119

2. Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271(11):840–4. PMID: 8114238

3. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016;37(38):2893–962. DOI: 10.1093/eurheartj/ehw210

4. Revishvili A.Sh., Shlyakhto E.V., Popov S.V., Pokushalov E.A., Shkolnikova M.A., Sulimov V.A. et al. Clinical recommendations for electrophysiological studies, catheter ablation and implantable antiarrhythmic devices. -M.: VNOA;2017. - 702 p. [Russian: Ревишвили А.Ш., Шляхто Е.В., Попов С.В., Покушалов Е.А., Школьникова М.А., Сулимов В.А. и др. Клинические рекомендации по проведению электрофизиологических исследований, катетерной аблации и применению имплантируемых антиаритмических устройств. - M.:ВНОА, 2017. - 702с. ISBN: 978-5-9500922-0-6 (Доступно на: http://webmed.irkutsk.ru/doc/pdf/vnoa.pdf)]

5. Lévy S, Maarek M, Coumel P, Guize L, Lekieffre J, Medvedowsky J-L et al. Characterization of Different Subsets of Atrial Fibrillation in General Practice in France: The ALFA Study. Circulation. 1999;99(23):3028–35. DOI: 10.1161/01.CIR.99.23.3028

6. Wyse DG, Van Gelder IC, Ellinor PT, Go AS, Kalman JM, Narayan SM et al. Lone Atrial Fibrillation: does it exist? Journal of the American College of Cardiology. 2014;63(17):1715–23. DOI: 10.1016/j.jacc.2014.01.023

7. Kolb C, Nürnberger S, Ndrepepa G, Zrenner B, Schömig A, Schmitt C. Modes of initiation of paroxysmal atrial fibrillation from analysis of spontaneously occurring episodes using a 12-lead Holter monitoring system. The American Journal of Cardiology. 2001;88(8):853–7. DOI: 10.1016/S0002-9149(01)01891-4

8. Jais P, Haissaguerre M, Shah DC, Chouairi S, Gencel L, Hocini M et al. A Focal Source of Atrial Fibrillation Treated by Discrete Radiofrequency Ablation. Circulation. 1997;95(3):572–6. DOI: 10.1161/01.CIR.95.3.572

9. Morel E, Meyronet D, Thivolet-Bejuy F, Chevalier P. Identification and distribution of interstitial Cajal cells in human pulmonary veins. Heart Rhythm. 2008;5(7):1063–7. DOI: 10.1016/j.hrthm.2008.03.057

10. Perez‐Lugones A, McMahon JT, Ratliff NB, Saliba WI, Schweikert RA, Marrouche NF et al. Evidence of Specialized Conduction Cells in Human Pulmonary Veins of Patients with Atrial Fibrillation. Journal of Cardiovascular Electrophysiology. 2003;14(8):803–9. DOI: 10.1046/j.1540-8167.2003.03075.x

11. Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Journal. 2010;31(19):2369–429. DOI: 10.1093/eurheartj/ehq278

12. Platonov PG, Mitrofanova LB, Orshanskaya V, Ho SY. Structural Abnormalities in Atrial Walls Are Associated With Presence and Persistency of Atrial Fibrillation But Not With Age. Journal of the American College of Cardiology. 2011;58(21):2225–32. DOI: 10.1016/j.jacc.2011.05.061

13. Mitrofanova L.B. Types of fibrosis and its prevalence in the Atria in atrial fibrillation against the background of coronary heart disease and rheumatism. Journal of Arrhythmology. 2014;75:10–6. [Russian: Митрофанова Л.Б. Виды фиброза и его распространенность в предсердиях при фибрилляции предсердий на фоне ишемической болезни сердца и ревматизма. Вестник аритмологии. 2014;75:10-6]

14. Batalov R.E., Rogovskaya Yu. V., Ryabov V.V., Tatarsky R.B., Sazono­va S.I., Khlynin M.S. et al. Idiopathic form of atrial fibrillation, inflammation and clinical results of radiofrequency ablation. Russian Journal of Cardiology. 2014;12:7–12. [Russian: Баталов Р.Е., Роговская Ю.В., Рябов В.В., Татарский Р.Б., Сазонова С.И., Хлынин М.С. и др. Идиопатическая форма фибрилляции предсердий, воспаление и клинические результаты радиочастотной абляции. Российский кардиологический журнал. 2014;12:7-12]. DOI: 10.15829/1560-4071-2014-12-7-12

15. Aguilar M, Qi XY, Huang H, Comtois P, Nattel S. Fibroblast Electrical Remodeling in Heart Failure and Potential Effects on Atrial Fibrillation. Biophysical Journal. 2014;107(10):2444–55. DOI: 10.1016/j.bpj.2014.10.014

16. Jalife J, Kaur K. Atrial remodeling, fibrosis, and atrial fibrillation. Trends in Cardiovascular Medicine. 2015;25(6):475–84. DOI: 10.1016/j.tcm.2014.12.015

17. Pellman J, Zhang J, Sheikh F. Myocyte-fibroblast communication in cardiac fibrosis and arrhythmias: Mechanisms and model systems. Journal of Molecular and Cellular Cardiology. 2016;94:22–31. DOI: 10.1016/j.yjmcc.2016.03.005

18. Nattel S, Burstein B, Dobrev D. Atrial Remodeling and Atrial Fibrillation: Mechanisms and Implications. Circulation: Arrhythmia and Electrophysiology. 2008;1(1):62–73. DOI: 10.1161/CIRCEP.107.754564

19. Goette A, Honeycutt C, Langberg JJ. Electrical Remodeling in Atrial Fibrillation: Time Course and Mechanisms. Circulation. 1996;94(11):2968–74. DOI: 10.1161/01.CIR.94.11.2968

20. Ausma J, Litjens N, Lenders M-H, Duimel H, Mast F, Wouters L et al. Time Course of Atrial Fibrillation-induced Cellular Structural Remodeling in Atria of the Goat. Journal of Molecular and Cellular Cardiology. 2001;33(12):2083–94. DOI: 10.1006/jmcc.2001.1472

21. Gherghiceanu M, Popescu LM. Cardiac telocytes – their junctions and functional implications. Cell and Tissue Research. 2012;348(2):265–79. DOI: 10.1007/s00441-012-1333-8

22. Gherghiceanu M, Popescu LM. Cardiomyocyte precursors and telocytes in epicardial stem cell niche: electron microscope images. Journal of Cellular and Molecular Medicine. 2010;14(4):871–7. DOI: 10.1111/j.1582-4934.2010.01060.x

23. Kostin S, Popescu LM. A distinct type of cell in myocardium: interstitial Cajal-like cells (ICLCs). Journal of Cellular and Molecular Medicine. 2009;13(2):295–308. DOI: 10.1111/j.1582-4934.2008.00668.x

24. Mitrofanova L.B., Khazratov A.O., Gurshchenkov A.V., Osadchii A.M., Gorshkov A.N., Galkovsky B.E. Morphological study of telocytes in the left atrium in patients with long-term persistent atrial fibrillation. Russian Journal of Cardiology. 2019;7:53–62. [Russian: Митрофанова Л.Б., Хазратов А.О., Гурщенков А.В., Осадчий А.М., Горшков А.Н., Гальковский Б.Э. Морфологическое исследование телоцитов в левом предсердии у пациентов с длительно персистирующей фибрилляцией предсердий. Российский кардиологический журнал. 2019;7:53-62]. DOI: 10.15829/1560-4071-2019-7-53-62

25. Röcken C, Peters B, Juenemann G, Saeger W, Klein HU, Huth C et al. Atrial Amyloidosis: An Arrhythmogenic Substrate for Persistent Atrial Fibrillation. Circulation. 2002;106(16):2091–7. DOI: 10.1161/01.CIR.0000034511.06350.DF

26. Mandache E, Gherghiceanu M, Macarie C, Kostin S, Popescu LM. Telocytes in human isolated atrial amyloidosis: ultrastructural remodelling. Journal of Cellular and Molecular Medicine. 2010;14(12):2739–47. DOI: 10.1111/j.1582-4934.2010.01200.x

27. Voigt N, Heijman J, Dobrev D. New antiarrhythmic targets in atrial fibrillation. Future Cardiology. 2015;11(6):645–54. DOI: 10.2217/fca.15.67

28. Noskova M.V. Inflammation and infection-unrecognized causes of atrial fibrillation. Annals of Arrhythmology. 2006;3(2):47–52. [Russian: Носкова М.В. Воспаление и инфекция — нераспознанные причины возникновения фибрилляции предсердий. Анналы аритмологии. 2006;3(2):47-52]

29. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O’Connell J et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation. 1996;93(5):841–2. DOI: 10.1161/01.CIR.93.5.841

30. Ministry of Health of Russian Federation. Myocarditis: clinical guidelines. KP153. Moscow. 2016. 57p. . [Russian: Министерство Здравоохранения Российской Федерации. Миокардиты: клинические рекомендации. КР153. Москва. 2016. 57с. Доступно на: http://webmed.irkutsk.ru/doc/pdf/fedmt.pdf]

31. Liu P, Martino T, Opavsky MA, Penninger J. Viral myocarditis: balance between viral infection and immune response. The Canadian Journal of Cardiology. 1996;12(10):935–43. PMID: 9191484

32. Kytö V, Sipilä J, Rautava P. The effects of gender and age on occurrence of clinically suspected myocarditis in adulthood. Heart. 2013;99(22):1681–4. DOI: 10.1136/heartjnl-2013-304449

33. Sekiguchi M, Take M. World survey of catheter biopsy of the heart. In: M. Sekiguchi, E.G. Olsen. Cardiomyopathy: Clinical, pathological and theoretical aspects. -Baltimore, USA: University Park Press;1988. -217–225 p.

34. Rogovskaya Y, Botalov R, Ryabov V. Histopathologic, Immunohistochemical Features and Profile of Viral Antigens in Patients with Myocarditis. Advanced Materials Research. 2015;1085:447–52. DOI: 10.4028/www.scientific.net/AMR.1085.447

35. Mahfoud F, Gartner B, Kindermann M, Ukena C, Gadomski K, Klingel K et al. Virus serology in patients with suspected myocarditis: utility or futility? European Heart Journal. 2011;32(7):897–903. DOI: 10.1093/eurheartj/ehq493

36. Kobayashi Y, Yazawa T, Baba T, Mukai H, Inoue S, Takeyama Y et al. Clinical, Electrophysiological, and Histopathological Observations in Supraventricular Tachycardia. Pacing and Clinical Electrophysiology. 1988;11(8):1154–67. DOI: 10.1111/j.1540-8159.1988.tb03967.x

37. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological Substrate of Atrial Biopsies in Patients With Lone Atrial Fibrillation. Circulation. 1997;96(4):1180–4. DOI: 10.1161/01.CIR.96.4.1180

38. Nanthakumar K, Lau YR, Plumb VJ, Epstein AE, Kay GN. Electrophysiological Findings in Adolescents With Atrial Fibrillation Who Have Structurally Normal Hearts. Circulation. 2004;110(2):117–23. DOI: 10.1161/01.CIR.0000134280.40573.D8

39. Vlachos K, Letsas KP, Korantzopoulos P, Liu T, Georgopoulos S, Bakalakos A et al. Prediction of atrial fibrillation development and progression: Current perspectives. World Journal of Cardiology. 2016;8(3):267–76. DOI: 10.4330/wjc.v8.i3.267

40. O’Neal W, Venkatesh S, Broughton ST, Griffin W, Soliman E. Biomarkers and the prediction of atrial fibrillation: state of the art. Vascular Health and Risk Management. 2016;12:297–303. DOI: 10.2147/VHRM.S75537

41. Thambidorai SK, Parakh K, Martin DO, Shah TK, Wazni O, Jasper SE et al. Relation of C-reactive protein correlates with risk of thromboembolism in patients with atrial fibrillation. The American Journal of Cardiology. 2004;94(6):805–7. DOI: 10.1016/j.amjcard.2004.06.011

42. Psychari SN, Apostolou TS, Sinos L, Hamodraka E, Liakos G, Kremastinos DTh. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. The American Journal of Cardiology. 2005;95(6):764–7. DOI: 10.1016/j.amjcard.2004.11.032

43. Watanabe T, Takeishi Y, Hirono O, Itoh M, Matsui M, Nakamura K et al. C-Reactive protein elevation predicts the occurrence of atrial structural remodeling in patients with paroxysmal atrial fibrillation. Heart and Vessels. 2005;20(2):45–9. DOI: 10.1007/s00380-004-0800-x

44. Lewicka E, Dudzińska-Gehrmann J, Dąbrowska-Kugacka A, Zagożdżon P, Liżewska A, Daniłowicz-Szymanowicz L et al. Neopterin and interleukin-6 as predictors of recurrent atrial fibrillation. The Anatolian Journal of Cardiology. 2015;16:563—571. DOI: 10.5152/AnatolJCardiol.2015.6272

45. Blagova OV, Nedostup AV, Kogan EA, Sulimov VA, Abugov SA, Kupriyanova AG et al. Myocardial Biopsy In "Idiopathic" Atrial Fibrillation And Other Arrhythmias: Nosological Diagnosis, Clinical And Morphological Parallels, And Treatment. Journal of Atrial Fibrillation. 2016;9(1):1414. DOI: 10.4022/jafib.1414

46. Dedkova A.A., Suslova T.E., Kologrivova I.V., Batalov R.E., Antonchenko I.V., Popov S.V. Factors of inflammation and markers of myocardial damage in atrial fibrillation. Journal of Arrhythmology. 2010;60:49–53. [Russian: Дедкова А.А., Суслова Т.Е., Кологривова И.В., Баталов Р.Е., Антонченко И.В., Попов С.В. Факторы воспаления и маркеры повреждения миокарда при фибрилляции предсердий. Вестник аритмологии. 2010;60:49-53]

47. Mitrofanova LB, Orshanskaya V, Ho SY, Platonov PG. Histological evidence of inflammatory reaction associated with fibrosis in the atrial and ventricular walls in a case-control study of patients with history of atrial fibrillation. Europace. 2016;18(suppl 4):iv156–62. DOI: 10.1093/europace/euw361

48. Caforio ALP, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal. 2013;34(33):2636–48. DOI: 10.1093/eurheartj/eht210

49. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U et al. The Role of Endomyocardial Biopsy in the Management of Cardiovascular Disease. Journal of the American College of Cardiology. 2007;50(19):1914–31. DOI: 10.1016/j.jacc.2007.09.008

50. Deckers JW, Hare JM, Baughman KL. Complications of transvenous right ventricular endomyocardial biopsy in adult patients with cardiomyopathy: A seven-year survey of 546 consecutive diagnostic procedures in a tertiary referral center. Journal of the American College of Cardiology. 1992;19(1):43–7. DOI: 10.1016/0735-1097(92)90049-S

51. Basso C, Calabrese F, Angelini A, Carturan E, Thiene G. Classification and histological, immunohistochemical, and molecular diagnosis of inflammatory myocardial disease. Heart Failure Reviews. 2013;18(6):673–81. DOI: 10.1007/s10741-012-9355-6

52. Ardashev A.V., Zhelyakov E.G., Dolgushina E.A., Rybachenko M.S., Mangutov D.A., Konev A.V. et al. Radiofrequency Ablation of Chronic Atrial Fibrillation By Combined Isolation of Pulmonary Veins and Anatomical Modification of Arrhythmia Substrate. Kardiologiia. 2009;49(1):39–46. [Russian: Ардашев А.В., Желяков Е.Г., Долгушина Е.А., Рыбаченко М.С., Мангутов Д.А., Конев А.В. и др. Радиочастотная катетерная абляция хронической формы фибрилляции предсердий методом изоляции легочных вен и анатомической модификации субстрата аритмии. Кардиология. 2009;49(1):39-46]

53. Khan AR, Khan S, Sheikh MA, Khuder S, Grubb B, Moukarbel GV. Catheter Ablation and Antiarrhythmic Drug Therapy as First- or Second-Line Therapy in the Management of Atrial Fibrillation: Systematic Review and Meta-Analysis. Circulation: Arrhythmia and Electrophysiology. 2014;7(5):853–60. DOI: 10.1161/CIRCEP.114.001853

54. Piccini JP, Lopes RD, Kong MH, Hasselblad V, Jackson K, Al-Khatib SM. Pulmonary Vein Isolation for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation: A Meta-Analysis of Randomized, Controlled Trials. Circulation: Arrhythmia and Electrophysiology. 2009;2(6):626–33. DOI: 10.1161/CIRCEP.109.856633

55. Ganesan AN, Shipp NJ, Brooks AG, Kuklik P, Lau DH, Lim HS et al. Long‐term Outcomes of Catheter Ablation of Atrial Fibrillation: A Systematic Review and Meta‐analysis. Journal of the American Heart Association. 2013;2(2):e004549. DOI: 10.1161/JAHA.112.004549

56. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen S-A et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design. Europace. 2012;14(4):528–606. DOI: 10.1093/europace/eus027

57. Kim M-N, Lee JJ, Kim S-A, Kim YH, Choi JI, Park S-M et al. The Difference of Predictors for Recurrence After Catheter Ablation of Non-Paroxysmal Atrial Fibrillation According to Follow-Up Period. International Heart Journal. 2014;55(4):312–8. DOI: 10.1536/ihj.13-370

58. Revishvili A.Sh., Nardaya Sh.G., Rzayev F.G., Mustapaeva Z.V., Kotanova E.S. Electrophysiological and clinical predictors of effectiveness of radiofrequency ablation in the pulmonary veins and left atrium in patients with persistent form of atrial fibrillation. Annals of Arrhythmology. 2014;11(1):46–53. [Russian: Ревишвили А.Ш., Нардая Ш.Г., Рзаев Ф.Г., Мустапаева З.В., Котанова Е.С. Электрофизиологические и клинические предикторы эффективности радиочастотной абляции легочных вен и левого предсердия у пациентов с персистирующей формой фибрилляции предсердий. Анналы аритмологии. 2014;11(1):46-53]. DOI: 10.15275/annaritmol.2014.1.6

59. Akoum N, Daccarett M, Mcgann C, Segerson N, Vergara G, Kuppahally S et al. Atrial Fibrosis Helps Select the Appropriate Patient and Strategy in Catheter Ablation of Atrial Fibrillation: A DE-MRI Guided Approach. Journal of Cardiovascular Electrophysiology. 2011;22(1):16–22. DOI: 10.1111/j.1540-8167.2010.01876.x

60. Matsuo S, Lellouche N, Wright M, Bevilacqua M, Knecht S, Nault I et al. Clinical Predictors of Termination and Clinical Outcome of Catheter Ablation for Persistent Atrial Fibrillation. Journal of the American College of Cardiology. 2009;54(9):788–95. DOI: 10.1016/j.jacc.2009.01.081

61. Gusev N.V. Molecular mechanisms of muscle contraction. Soros educational journal. 2000;6(8):24–32. [Russian: Гусев Н.Б. Молекулярные механизмы мышечного сокращения. Соросовский образовательный журнал. 2000;6(8):24-32. Доступно на: http://journal.issep.rssi.ru/articles/pdf/0008_024.pdf]

62. Okagaki T, Weber FE, Fischman DA, Vaughan KT, Mikawa T, Reinach FC. The major myosin-binding domain of skeletal muscle MyBP-C (C protein) resides in the COOH-terminal, immunoglobulin C2 motif. The Journal of Cell Biology. 1993;123(3):619–26. DOI: 10.1083/jcb.123.3.619

63. Squire JM, Luther PK, Knupp C. Structural Evidence for the Interaction of C-protein (MyBP-C) with Actin and Sequence Identification of a Possible Actin-binding Domain. Journal of Molecular Biology. 2003;331(3):713–24. DOI: 10.1016/S0022-2836(03)00781-2

64. Whitten AE, Jeffries CM, Harris SP, Trewhella J. Cardiac myosin-binding protein C decorates F-actin: Implications for cardiac function. Proceedings of the National Academy of Sciences. 2008;105(47):18360–5. DOI: 10.1073/pnas.0808903105

65. Sadayappan S, de Tombe PP. Cardiac myosin binding protein-C as a central target of cardiac sarcomere signaling: a special mini review series. Pflügers Archiv - European Journal of Physiology. 2014;466(2):195–200. DOI: 10.1007/s00424-013-1396-8

66. Govindan S, McElligott A, Muthusamy S, Nair N, Barefield D, Martin JL et al. Cardiac myosin binding protein-C is a potential diagnostic biomarker for myocardial infarction. Journal of Molecular and Cellular Cardiology. 2012;52(1):154–64. DOI: 10.1016/j.yjmcc.2011.09.011

67. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie ANJ, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. Journal of Clinical Investigation. 2007;117(6):1538–49. DOI: 10.1172/JCI30634

68. Gadina M, Jefferies CA. IL-33: A Sheep in Wolf’s Clothing? Science Signaling. 2007;2007(390):pe31–pe31. DOI: 10.1126/stke.3902007pe31

69. Shah RV, Januzzi JL. ST2: A Novel Remodeling Biomarker in Acute and Chronic Heart Failure. Current Heart Failure Reports. 2010;7(1):9–14. DOI: 10.1007/s11897-010-0005-9